Management of clinically node-negative early-stage oral cancer: network meta-analysis of randomized clinical trials

E A Al-Moraissi1, A S Alkhutari1, R de Bree2

  • 1Department of Oral and Maxillofacial Surgery, Thamar University, Thamar, Yemen.

Insights

Elective neck dissection (END) is likely the best treatment for early-stage oral squamous cell carcinoma (OSCC) with a clinically node-negative neck, offering improved survival and reduced recurrence compared to therapeutic neck dissection (TND). Sentinel lymph node biopsy (SLNB) shows comparable results to END but requires further research.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Head and Neck Surgery

Background:

  • Optimal management of the clinically node-negative (cN0) neck in early-stage oral squamous cell carcinoma (OSCC) lacks consensus.
  • Existing treatment options include therapeutic neck dissection (TND), sentinel lymph node biopsy (SLNB), and elective neck dissection (END).

Purpose of the Study:

  • To conduct a network meta-analysis (NMA) of randomized clinical trials (RCTs) to determine the most effective treatment for the cN0 neck in early-stage OSCC.
  • To rank treatments based on effectiveness for overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), and nodal recurrence.

Main Methods:

  • A systematic literature search adhering to PRISMA guidelines identified relevant RCTs comparing TND, SLNB, and END.
  • Direct meta-analysis and NMA were performed to calculate hazard ratios and risk ratios for key outcomes.
  • Ten RCTs involving 1858 patients were included in the analysis.

Main Results:

  • Direct meta-analysis indicated END was superior to TND and comparable to SLNB.
  • NMA showed no significant difference between END and SLNB for OS, DSS, DFS, and nodal recurrence (very low quality evidence).
  • END significantly improved OS and DFS, and reduced nodal recurrence compared to TND (moderate quality evidence). END ranked highest, followed by SLNB and TND.

Conclusions:

  • Elective neck dissection (END) is a favorable treatment for the cN0 neck in early-stage OSCC, supported by moderate-quality evidence.
  • Sentinel lymph node biopsy (SLNB) shows promise but requires more extensive research, particularly regarding its efficacy in detecting contralateral metastases and its long-term outcomes.
  • Further studies are needed to compare the morbidity, quality of life, and costs associated with different neck management strategies in early-stage OSCC.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.8K